 |
|
|
| |
POPULATION PHARMACOKINETIC ANALYSIS OF DOLUTEGRAVIR IN HIV/TB COINFECTED
PEOPLE WITH AND WITHOUT RIFAMPICIN
|
| |
| |
17th European AIDS Conference, November 6-9, 2019, Basel
Reported by Jules Levin
Rajendra Singh,1 Hardik Chandasana,1 Kelly E. Dooley,2 Richard Kaplan,3 Noluthando Mwelase,4 Beatriz Grinsztejn,5 Eduardo Ticona,6 Marcus Lacerda,7 Omar Sued,8 Elena Belonosova,9
Mounir Ait-Khaled,10 Konstantinos Angelis,11 Dannae Brown,12 Christine L. Talarico,13 Allan R. Tenorio,13 Michael R. Keegan,10 Michael Aboud,10 for the INSPIRING study group
1Clinical Pharmacology Modeling Simulation, GlaxoSmithKline, Collegeville, PA, USA; 2Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 3Desmond Tutu HIV Foundation, Cape Town,
South Africa; 4Clinical HIV Research Unit, Johannesburg, South Africa; 5Instituto de Pesquisa Clínica Evandro Chagas FIOCRUZ, Rio de Janeiro, Brazil; 6Hospital Nacional Dos de Mayo, Universidad Nacional Mayor de San Marcos, Lima, Peru; 7Instituto Leônidas & Maria Deane (Fiocruz)/Tropical Medicine Foundation Dr Heitor Vieira Dourado, Manaus, Brazil; 8Fundación Huésped, Buenos Aires, Argentina; 9Regional Center for Prevention and Treatment of AIDS and Infectious Diseases, Russia; 10ViiV Healthcare, Brentford, UK; 11GlaxoSmithKline, Stockley Park, Uxbridge, UK; 12ViiV Healthcare, Abbotsford, VIC, Australia; 13ViiV Healthcare, Research Triangle Park, NC, USA
Reference: Dooley KE, Kaplan R, Mwelase N, et al. "Dolutegravir-based antiretroviral therapy for patients
co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial." Clinical
Infectious Diseases (2019)
|
| |
|
|
|
|
|
